Clinical trial of phase II for the a front line treatment of the non-Hodgkin lymphomas of derivation lymphocyte T Gemcitabine and Oxaliplatin GEMOX

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004675-11-IT

Enrollment

100

Registered

2006-03-15

Start date

2004-09-14

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Hodgkin s disease of lymphocyte T derivation MedDRA version: 6.1 Level: HLGT Classification code 10025321

Interventions

Trade Name: GEMZAR 1G POLV. EV 1 FL Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Gemcitabine CAS Number: 122111-03-9 Concentration unit: g gram(s) Concentrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026